Inappropriate use of progression-free survival in cancer drug approvals

Editorial is in agreement with growing number of oncologists who have called for new cancer drugs to be approved on basis of their overall survival or quality of life benefits, and preferably both so that drugs are approved based on outcomes most important to patients.

British Medical Journal